about
The synergistic effect of everolimus and chloroquine on endothelial cell number reduction is paralleled by increased apoptosis and reduced autophagy occurrenceNew targets, new drugs for metastatic bone pain: a new philosophy.New molecular targets in bone metastases.Deregulation of dicer and mir-155 expression in liposarcoma.Antagonistic effects of chloroquine on autophagy occurrence potentiate the anticancer effects of everolimus on renal cancer cellsCetuximab: from bench to bedside.Targeting EGFR in bilio-pancreatic and liver carcinoma.Premetastatic niche: ready for new therapeutic interventions?Emerging strategies to overcome the resistance to current mTOR inhibitors in renal cell carcinoma.MicroRNAs and bone metastasis: a new challenge.Emerging drugs for the treatment of bone metastasis.Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment.Cetuximab in small bowel adenocarcinoma: a new friend?Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw.Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients.Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients.Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing antiretroviral therapy.Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study).Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study.Should oncologists be aware in their clinical practice of KRAS molecular analysis?Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate cancer neoadjuvant setting.PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patientsDynamic changes of Receptor activator of nuclear factor-κB expression in Circulating Tumor Cells during Denosumab predict treatment effectiveness in Metastatic Breast Cancer
P50
Q28534969-922B9BE9-5A13-49ED-98E5-68E69E9D66A1Q30403253-0CFD757F-BD5E-4363-94F4-A0FCC995B4A4Q34024907-B43DC709-3D11-4F7C-9AF8-30CBC1AB8A7FQ35833073-93083B6E-A73A-454C-AD59-586751D740C9Q36212757-03AC675E-4E1F-4200-AFD2-AA9B16AC0D84Q37678510-966DB4CD-0468-44A1-B9A9-D04A0B17C492Q37825280-6E226D9E-64AD-4D16-9F79-40C7C91410ACQ37996455-ED4B9BC1-796D-47A9-9D8E-BE3A0A771AC3Q38183537-40563AA8-CA1E-4383-892B-CD2A7CABC577Q38229107-ADE6AFC6-30F5-439D-976F-AFB96FD31158Q38538263-CFA0EF03-A7E0-43B5-9EA9-E22A4B66DD9FQ41261499-F8695CC3-C005-4026-9163-7C9B344A6E1EQ42392535-6820F33F-D53E-49AB-9B32-B66A9F70FE06Q42424855-1A304034-D94E-4159-B6F6-F94A858F3969Q42480495-2CE47084-05D0-4292-93A3-5F2F76E0CF99Q43247707-70EB1C59-C513-4AA1-B7B5-7287BAC9A7E0Q44456563-6D961385-261E-48DD-B031-E5BDE6148AEAQ53216963-290D1DC9-C6BB-4AE3-A303-EDAFC15CF51CQ54278445-9E5E67BE-7DE9-47F9-98E2-EC9C1EC52F47Q54373423-A35F41A3-6F3B-4332-A538-CD6393A471E3Q54391227-E52EB090-B8B9-44FF-9AC7-88339B88213FQ54444545-E9C04F8D-3240-410F-984B-CB1227FC046EQ60530493-1AF9F6D5-6098-4B39-BED9-672575CF9C15Q93012639-C009D2EB-F1CB-4F5A-A080-21B599702FC8
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alice Zoccoli
@ast
Alice Zoccoli
@en
Alice Zoccoli
@es
Alice Zoccoli
@nl
Alice Zoccoli
@sl
type
label
Alice Zoccoli
@ast
Alice Zoccoli
@en
Alice Zoccoli
@es
Alice Zoccoli
@nl
Alice Zoccoli
@sl
prefLabel
Alice Zoccoli
@ast
Alice Zoccoli
@en
Alice Zoccoli
@es
Alice Zoccoli
@nl
Alice Zoccoli
@sl
P106
P21
P31
P496
0000-0003-1991-1667